Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2018-11-21 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2018-11-21 English
10-Q
Interim / Quarterly Report Q3 2018
2018-10-31 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 31, 2018, reporting the results of operations and financial condition for the quarter ended September 30, 2018. It references a press release (Exhibit 99.1) containing the financial results. The text explicitly states that the information is being furnished and not filed, and it is a current report rather than a full quarterly or annual report. The document length is 3596 characters, which is relatively short and mainly serves as an announcement of the earnings release rather than containing detailed financial statements or analysis. Therefore, this document is best classified as an Earnings Release (ER) announcement rather than a full Interim/Quarterly Report (IR).
2018-10-31 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 1, 2018, reporting the departure of two senior officers of Innoviva, Inc. It details the termination of employment and separation agreements for these officers. The key section is Item 5.02, which pertains to the departure and appointment of directors or officers. There is no financial data or report content, only announcements about management changes. According to the filing definitions, announcements of changes in senior management fall under Board/Management Information (MANG). The document is not a full financial report, earnings release, or regulatory filing of another type. Therefore, the correct classification is MANG with high confidence.
2018-10-04 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 26, 2018. The key content is under Item 5.02, which reports the departure of two senior officers of the company. There is no financial data, earnings information, or report publication mentioned. The primary focus is on management changes, specifically termination of employment of senior executives. According to the filing definitions, announcements of changes in senior management fall under Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS. Therefore, the correct classification is MANG with high confidence.
2018-10-01 English
FORM 4
Director's Dealing
2018-09-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.